Claudia Augello1, Umberto Gianelli2, Federica Savi3, Alessia Moro3, Emanuela Bonoldi4, Marcello Gambacorta5, Valentina Vaira6, Luca Baldini7, Silvano Bosari8. 1. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 2. Hematopathology Section, Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy. 3. Division of Pathology, San Paolo Hospital, Milan, Italy. 4. Division of Pathology, A.Manzoni Hospital, Lecco, Italy. 5. Department of Laboratory Medicine, Niguarda Ca' Granda Hospital, Milan, Italy. 6. Division of Pathology, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy. 7. Division of Hematology, Department of Clinical and Community Sciences, University of Milan, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy. 8. Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Ca' Granda-Maggiore Policlinico Hospital Foundation, Milan, Italy.
Abstract
AIMS: To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. METHODS: In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. RESULTS: A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. CONCLUSIONS: These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. METHODS: In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. RESULTS: A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. CONCLUSIONS: These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.